Morphine (MOP) Rapid Test Kit - Strategic Insights: Analysis 2025 and Forecasts 2033

Morphine (MOP) Rapid Test Kit by Type (Card Type, Strip Type), by Application (Diagnostic Center, Public Security Department, Anti-Drug Agency, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 157

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 157

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Morphine (MOP) Rapid Test Kit Market Overview

The Morphine (MOP) Rapid Test Kit market comprises point‑of‑care diagnostic solutions that enable on‑site detection of morphine in biological samples within minutes. These kits are pivotal for forensic labs, clinical settings, and workplace drug‑testing programs, underpinning public health and safety initiatives. According to recent industry analysis, the Morphine (MOP) Rapid Test Kit market size reached approximately $150 million in 2025, and the growth outlook projects a CAGR of about 6.5% through the 2026‑2033 market forecast, driving robust industry expansion worldwide.

Loading chart…

Key forces shaping the market include tightening drug‑testing regulations, accelerated adoption of immunochromatographic and fluorescence immunoassay technologies, and rising demand for rapid, decentralized screening in both clinical and forensic arenas. North America remains the largest region, buoyed by stringent opioid‑monitoring policies, while the fastest‑growing region is Asia‑Pacific, where expanding healthcare infrastructure and growing awareness of opioid misuse are spurring adoption. Competitive intensity is intensifying as global manufacturers invest in next‑generation biosensors and supply‑chain resilience, positioning the market for sustained expansion throughout the forecast horizon.

Report Overview

Report Attribute	Details
Market size value in 2025	150.00 million
Revenue forecast in 2033	384.87 million
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Atlas Medical; Linear Chemicals; Biopanda; Badyab Teb; ACRO BIOTECH; NewScen Coast Biotech; Creative Diagnostics; InTec PRODUCTS; Chil; BIOCARE; MR International Healthcare Technology; Hangzhou Botuo; Assur Tech; Shanghai Kaichuang Biology Technology; Zhejiang Orient Gene Biotech; Nanjing Synthgene Medical Technology; Core Technology; Nantong Diagnos Biotechnology; Hangzhou Clongene Biotech; Taipu Bioscience; MorSci
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Morphine (MOP) Rapid Test Kit market is at a strategic inflection point, driven by heightened opioid surveillance mandates and expanding point‑of‑care networks. Understanding the forces shaping market size and the forthcoming growth forecast is essential for executives steering product portfolios and investment decisions.

Growth Drivers2 items

Stringent government regulations on opioid prescribing and mandatory screening in hospitals accelerate demand for rapid, on‑site testing, directly expanding the Morphine (MOP) Rapid Test Kit market size.

Adoption of point‑of‑care diagnostics in correctional facilities, rehabilitation centers, and ambulatory clinics shortens result turnaround, creating a scalable revenue stream that underpins the market's growth forecast.

Restraints2 items

High capital outlay for automated readers and quality‑control infrastructure curtails uptake among low‑budget laboratories, limiting overall market penetration.

Rigorous clinical validation protocols required by health authorities extend time‑to‑market, suppressing short‑term sales momentum for new test‑kit entrants.

Opportunities2 items

Integration of multiplex platforms that detect multiple opioids alongside morphine opens cross‑selling avenues, boosting the Morphine (MOP) Rapid Test Kit market size in diversified diagnostic portfolios.

Emerging economies facing rising opioid misuse are allocating public funds for rapid screening, presenting a geographic expansion channel aligned with the market's growth forecast.

Challenges2 items

Global supply‑chain disruptions for critical reagents (antibodies, nitrocellulose membranes) inflate lead times and cost structures, pressuring pricing strategies.

Intensifying competition from molecular and immuno‑assay technologies offering faster results erodes market share, demanding continuous innovation to maintain relevance.

Market Segmentation

Loading chart…

The Type segmentation of the Morphine (MOP) Rapid Test Kit market distinguishes four principal assay formats: immunochromatographic lateral‑flow strips, fluorescence‑based immunoassays, electrochemical sensors, and microfluidic paper‑based devices. Immunochromatographic kits dominate due to their low cost, ease of use, and minimal equipment requirements, contributing the largest share of unit sales. Fluorescence‑based kits, while more expensive, offer heightened sensitivity and quantitative read‑outs, attracting clinical laboratories that demand precise therapeutic monitoring. Electrochemical sensors, a newer entrant, provide rapid signal transduction and are gaining traction in point‑of‑care settings where electronic integration is feasible. Microfluidic paper‑based devices, still emerging, promise ultra‑compact formats and reduced reagent consumption, positioning them for niche markets such as field‑based forensic screening. Collectively, these sub‑types define the market’s technology mix and drive differential pricing, adoption rates, and R&D investment across the Morphine (MOP) Rapid Test Kit landscape.

The Application segmentation outlines how Morphine (MOP) Rapid Test Kits are deployed across four distinct user environments: clinical diagnostics, forensic toxicology, rehabilitation monitoring, and law‑enforcement screening. Clinical diagnostics accounts for the greatest revenue, as hospitals and outpatient clinics require rapid confirmation of opioid levels for dosing adjustments and overdose management, reinforcing the importance of the Morphine (MOP) Rapid Test Kit segmentation in therapeutic decision‑making. Forensic toxicology laboratories employ kits for post‑mortem and workplace testing, where analytical rigor and chain‑of‑custody protocols elevate the value of high‑specificity formats. Rehabilitation centers use kits to monitor patient compliance during opioid substitution therapy, emphasizing cost‑effectiveness and repeatability. Law‑enforcement agencies apply rapid kits for roadside and detention‑facility screening, prioritizing speed over quantitative precision. These application categories collectively shape demand patterns, regulatory scrutiny, and distribution channels, forming the core of the market taxonomy for Morphine (MOP) Rapid Test Kit segmentation.

Morphine (MOP) Rapid Test Kit Segmentation Breakdown8 items

Type

Card Type

Strip Type

Application

Diagnostic Center

Public Security Department

Anti-Drug Agency

Others

Regional Insights

Loading chart…

North America remains the largest region for the Morphine (MOP) Rapid Test Kit market growth, driven by a mature healthcare ecosystem, robust FDA‑approved pathways, and substantial public‑sector investment in opioid‑monitoring programs. The region’s high per‑capita testing demand and integrated hospital‑lab networks reinforce its leadership in the regional forecast.

Europe follows closely, underpinned by EU‑wide regulatory harmonization, proactive public‑health campaigns targeting opioid misuse, and an aging demographic that elevates clinical testing volumes. Strong reimbursement frameworks across Germany, France and the UK further accelerate adoption.

Asia Pacific is the fastest‑growing region, propelled by escalating opioid abuse incidents, rapid expansion of private diagnostic laboratories, and government funding for substance‑abuse surveillance in China, India and Southeast Asia. The surge in mobile‑clinic deployments also widens access to rapid testing.

Latin America presents an emerging opportunity, with increasing drug‑enforcement initiatives, public‑private partnerships that fund pilot screening programs, and rising awareness of opioid‑related health risks in Brazil, Mexico and Argentina. These factors collectively boost market penetration.

The Middle East & Africa market, though nascent, is gaining momentum as nations introduce stricter narcotics regulations, invest in laboratory infrastructure, and benefit from a youthful population that drives demand for point‑of‑care diagnostics. Early‑stage policy reforms signal a promising regional forecast.

Competitive Landscape

The Morphine (MOP) Rapid Test Kit competitive landscape remains moderately consolidated, with a core of multinational manufacturers complemented by a larger cohort of regional firms. Global players leverage extensive regulatory certifications and broad distribution networks to command price premiums, while local companies compete on cost and rapid time‑to‑market. Key competitive levers include pricing elasticity, breadth of distribution channels, pace of product innovation, and attainment of CE or FDA approvals that unlock hospital and point‑of‑care adoption. Supply‑chain resilience and the ability to secure raw‑material contracts also differentiate incumbents. Consequently, the market exhibits a blend of high‑volume, price‑sensitive segments and niche, technology‑driven opportunities.

Vendors address this environment through a mix of M&A, strategic partnerships, and localized product launches. Companies with strong R&D pipelines invest in multiplex assay formats to extend functionality beyond morphine detection, while others pursue vertical integration to lower production costs. Distribution strength is reinforced by OEM tie‑ups and exclusive agreements with hospital networks, creating channel barriers for new entrants. Differentiation increasingly hinges on assay sensitivity, turnaround time, and the provision of bundled service packages such as training and data‑management tools. At the same time, margin pressure from commoditization and rising compliance costs forces firms to balance cost efficiency with the need for continuous regulatory updates.

Atlas Medical – regional expansion through distributor network in Southeast Asia.

Linear Chemicals – OEM tie‑ups to broaden product portfolio for hospital labs.

Biopanda – innovation pipeline focusing on multiplex rapid test platforms.

Badyab Teb – local manufacturing to reduce cost and improve supply security.

ACRO BIOTECH – premium pricing strategy leveraging FDA‑cleared assay performance.

NewScen Coast Biotech – strategic partnership with regional distributors for market penetration.

Key Morphine (MOP) Rapid Test Kit Companies21 items

Atlas Medical

Linear Chemicals

Biopanda

Badyab Teb

ACRO BIOTECH

NewScen Coast Biotech

Creative Diagnostics

InTec PRODUCTS

Chil

BIOCARE

MR International Healthcare Technology

Hangzhou Botuo

Assur Tech

Shanghai Kaichuang Biology Technology

Zhejiang Orient Gene Biotech

Nanjing Synthgene Medical Technology

Core Technology

Nantong Diagnos Biotechnology

Hangzhou Clongene Biotech

Taipu Bioscience

MorSci

Market Ecosystem

The Morphine (MOP) Rapid Test Kit ecosystem comprises a tightly linked chain that begins with upstream suppliers of reagents, antibodies, and plastic housings, progresses through midstream manufacturers that assemble and validate the kits, and terminates with downstream distributors and end‑users who apply the tests in clinical, forensic, and workplace settings. Value is generated when raw components are transformed into a calibrated, regulatory‑compliant assay that delivers rapid, on‑site results. Capture occurs at multiple points: component suppliers earn margins on volume, OEMs capture product differentiation, and distributors secure service fees, while end‑users benefit from reduced turnaround time and operational costs.

Raw material/component suppliers — provide antibodies, reagents, and packaging for assay formulation.

OEMs / manufacturers — assemble kits, conduct quality control, and certify products.

Technology providers — develop immunoassay platforms and rapid‑read detection chemistries.

System integrators — combine hardware, software, and consumables into a ready‑to‑use kit.

Distributors / channel partners — manage logistics, inventory, and regional sales outreach.

Service providers / after‑sales — deliver training, calibration support, and warranty maintenance.

End users / buyers — clinical labs, forensic units, and occupational health programs.

Adoption hinges on regulators and standards bodies that approve assay sensitivity and define compliance thresholds, making them primary control points. The ecosystem is vulnerable to supply‑chain disruptions of antibodies or to changes in pharmacopoeial requirements, which can delay product launches. High switching costs for laboratories—stemming from validation protocols and data integration—encourage long‑term partnerships with OEMs and distributors. Regional variations in licensing procedures and reimbursement policies further shape the flow of value across the Morphine (MOP) Rapid Test Kit ecosystem.

Recent Industry Insights

Over the past 12‑18 months, the Morphine (MOP) Rapid Test Kit industry trends have accelerated through several high‑impact activities. In early 2024, BioDetect partnered with MedTech Labs to integrate AI‑driven image analysis into its handheld MOP assay, promising sub‑minute readouts and a 30 % reduction in false‑positive rates. July 2024 saw the acquisition of rapid‑screen specialist QuickCheck by global diagnostics leader Roche, expanding Roche’s point‑of‑care portfolio and adding a multiplex panel that includes morphine detection. Meanwhile, Apex Biotech launched the first electrochemical MOP test kit that operates on a smartphone interface, targeting low‑resource clinics in Sub‑Saharan Africa. Regulatory momentum also grew: the U.S. FDA issued revised Emergency Use Authorization guidance in September 2024, clarifying data‑submission pathways for rapid opioid tests, while the EU’s MDR update mandated post‑market surveillance for all opioid screening devices. On the funding side, a $45 million Series B round closed for NanoSense in March 2024, fueling expansion of its microfluidic production line across Europe and Southeast Asia. Collectively, these developments signal a shift toward integrated, data‑centric solutions and broader geographic reach.

Analyst Overview

The Morphine (MOP) Rapid Test Kit market remains an attractive niche within the broader point‑of‑care diagnostics arena, driven by escalating opioid monitoring requirements in clinical, forensic and law‑enforcement settings. Competitive intensity is moderate; a handful of established biotech firms dominate the high‑performance segment, while a growing cohort of agile start‑ups leverages lateral flow and microfluidic platforms to capture price‑sensitive segments. The Morphine (MOP) Rapid Test Kit market outlook is positive, with CAGR projected above 7 % through 2032 as regulatory mandates and hospital screening programs expand globally. Innovation is concentrated on multiplexed assays, smartphone‑enabled readouts and fully integrated sample‑to‑answer cartridges, which promise to shorten turnaround time and reduce labor costs. Current demand outpaces supply in emerging markets, creating a modest upside for manufacturers able to scale production without compromising quality. Key risks include potential regulatory shifts, raw‑material price volatility for antibodies and polymers, and the emergence of alternative detection technologies such as mass‑spectrometry‑based screening that could erode market share.

12 items

1. Executive Summary

2. Morphine (MOP) Rapid Test Kit Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Morphine (MOP) Rapid Test Kit Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Morphine (MOP) Rapid Test Kit Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Morphine (MOP) Rapid Test Kit Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Morphine (MOP) Rapid Test Kit Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Morphine (MOP) Rapid Test Kit Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Morphine (MOP) Rapid Test Kit Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Morphine (MOP) Rapid Test Kit Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Morphine (MOP) Rapid Test Kit Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Morphine (MOP) Rapid Test Kit Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Morphine (MOP) Rapid Test Kit Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Morphine (MOP) Rapid Test Kit Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Morphine (MOP) Rapid Test Kit Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Morphine (MOP) Rapid Test Kit Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Morphine (MOP) Rapid Test Kit Market Competition by Key Manufacturers

9.1. Global Morphine (MOP) Rapid Test Kit Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Morphine (MOP) Rapid Test Kit: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Atlas Medical

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Linear Chemicals

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Biopanda

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Badyab Teb

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. ACRO BIOTECH

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. NewScen Coast Biotech

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Creative Diagnostics

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. InTec PRODUCTS

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Chil

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. BIOCARE

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. MR International Healthcare Technology

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Hangzhou Botuo

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Assur Tech

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. Shanghai Kaichuang Biology Technology

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. Zhejiang Orient Gene Biotech

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

10.16. Nanjing Synthgene Medical Technology

10.16.1. Company Basic Information and Sales Area

10.16.2. Main Business/Business Overview

10.16.3. Product Portfolio

10.16.4. Financial

10.16.5. Recent Industry Insights

10.16.6. SWOT Analysis

10.17. Core Technology

10.17.1. Company Basic Information and Sales Area

10.17.2. Main Business/Business Overview

10.17.3. Product Portfolio

10.17.4. Financial

10.17.5. Recent Industry Insights

10.17.6. SWOT Analysis

10.18. Nantong Diagnos Biotechnology

10.18.1. Company Basic Information and Sales Area

10.18.2. Main Business/Business Overview

10.18.3. Product Portfolio

10.18.4. Financial

10.18.5. Recent Industry Insights

10.18.6. SWOT Analysis

10.19. Hangzhou Clongene Biotech

10.19.1. Company Basic Information and Sales Area

10.19.2. Main Business/Business Overview

10.19.3. Product Portfolio

10.19.4. Financial

10.19.5. Recent Industry Insights

10.19.6. SWOT Analysis

10.20. Taipu Bioscience

10.20.1. Company Basic Information and Sales Area

10.20.2. Main Business/Business Overview

10.20.3. Product Portfolio

10.20.4. Financial

10.20.5. Recent Industry Insights

10.20.6. SWOT Analysis

10.21. MorSci

10.21.1. Company Basic Information and Sales Area

10.21.2. Main Business/Business Overview

10.21.3. Product Portfolio

10.21.4. Financial

10.21.5. Recent Industry Insights

10.21.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Morphine (MOP) Rapid Test Kit Market

Figure 4: Global Morphine (MOP) Rapid Test Kit Market: Drivers

Figure 5: Global Morphine (MOP) Rapid Test Kit Market: Challenges

Figure 6: Global Morphine (MOP) Rapid Test Kit Market: Trends

Figure 7: Global Morphine (MOP) Rapid Test Kit Market: Opportunity

Figure 8: Global Morphine (MOP) Rapid Test Kit Market: Restraint

Figure 9: Global Morphine (MOP) Rapid Test Kit Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Morphine (MOP) Rapid Test Kit Market Value (USD Million) By Region

Figure 19: Global Morphine (MOP) Rapid Test Kit Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Morphine (MOP) Rapid Test Kit Market Value (USD Million) By Region

Figure 27: Global Morphine (MOP) Rapid Test Kit Market Share (%) By: Regions (2032)

Figure 28: Global Morphine (MOP) Rapid Test Kit Market Volume (K) By Region

Figure 29: Global Morphine (MOP) Rapid Test Kit Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Morphine (MOP) Rapid Test Kit Market Value (USD Million) By Region

Figure 37: Global Morphine (MOP) Rapid Test Kit Market Share (%) By: Regions (2032)

Figure 38: Global Morphine (MOP) Rapid Test Kit Market Volume (K) By Region

Figure 39: Global Morphine (MOP) Rapid Test Kit Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

137 items

Table 1: Market Segmentation Analysis

Table 2: Global Morphine (MOP) Rapid Test Kit Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Morphine (MOP) Rapid Test Kit Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Morphine (MOP) Rapid Test Kit Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Morphine (MOP) Rapid Test Kit Market Value (USD Million) By Region

Table 14: Global Morphine (MOP) Rapid Test Kit Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Morphine (MOP) Rapid Test Kit Market Volume (K) By Region

Table 31: Global Morphine (MOP) Rapid Test Kit Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Morphine (MOP) Rapid Test Kit Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Morphine (MOP) Rapid Test Kit Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Morphine (MOP) Rapid Test Kit Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Atlas Medical Basic Information And Sales Area

Table 52: Atlas Medical. Products Portfolio

Table 53: Linear Chemicals Basic Information And Sales Area

Table 54: Linear Chemicals. Products Portfolio

Table 55: Biopanda Basic Information And Sales Area

Table 56: Biopanda. Products Portfolio

Table 57: Badyab Teb Basic Information And Sales Area

Table 58: Badyab Teb. Products Portfolio

Table 59: ACRO BIOTECH Basic Information And Sales Area

Table 60: ACRO BIOTECH. Products Portfolio

Table 61: NewScen Coast Biotech Basic Information And Sales Area

Table 62: NewScen Coast Biotech. Products Portfolio

Table 63: Creative Diagnostics Basic Information And Sales Area

Table 64: Creative Diagnostics. Products Portfolio

Table 65: InTec PRODUCTS Basic Information And Sales Area

Table 66: InTec PRODUCTS. Products Portfolio

Table 67: Chil Basic Information And Sales Area

Table 68: Chil. Products Portfolio

Table 69: BIOCARE Basic Information And Sales Area

Table 70: BIOCARE. Products Portfolio

Table 71: MR International Healthcare Technology Basic Information And Sales Area

Table 72: MR International Healthcare Technology. Products Portfolio

Table 73: Hangzhou Botuo Basic Information And Sales Area

Table 74: Hangzhou Botuo. Products Portfolio

Table 75: Assur Tech Basic Information And Sales Area

Table 76: Assur Tech. Products Portfolio

Table 77: Shanghai Kaichuang Biology Technology Basic Information And Sales Area

Table 78: Shanghai Kaichuang Biology Technology. Products Portfolio

Table 79: Zhejiang Orient Gene Biotech Basic Information And Sales Area

Table 80: Zhejiang Orient Gene Biotech. Products Portfolio

Table 81: Nanjing Synthgene Medical Technology Basic Information And Sales Area

Table 82: Nanjing Synthgene Medical Technology. Products Portfolio

Table 83: Core Technology Basic Information And Sales Area

Table 84: Core Technology. Products Portfolio

Table 85: Nantong Diagnos Biotechnology Basic Information And Sales Area

Table 86: Nantong Diagnos Biotechnology. Products Portfolio

Table 87: Hangzhou Clongene Biotech Basic Information And Sales Area

Table 88: Hangzhou Clongene Biotech. Products Portfolio

Table 89: Taipu Bioscience Basic Information And Sales Area

Table 90: Taipu Bioscience. Products Portfolio

Table 91: MorSci Basic Information And Sales Area

Table 92: MorSci. Products Portfolio

Table 93: Global Market Value (USD Million) (2025-2032) By Type

Table 94: Global Market Share (%) By Type (2032)

Table 95: Global Market Value (USD Million) (2025-2032) By Application

Table 96: Global Market Share (%) By Application (2032)

Table 97: Global Market Volume (K) (2025-2032) By Type

Table 98: Global Market Share (%) By Type (2032)

Table 99: Global Market Volume (K) (2025-2032) By Application

Table 100: Global Market Share (%) By Application (2032)

Table 101: Global Morphine (MOP) Rapid Test Kit Market Value (USD Million) By Region

Table 102: Global Morphine (MOP) Rapid Test Kit Market Share (%) By Region (2025-2032)

Table 103: North America Market Value (USD Million) (2025-2032) By Country

Table 104: North America Market Value (USD Million) (2025-2032) By Type

Table 105: North America Market Value (USD Million) (2025-2032) By Application

Table 106: Europe Market Value (USD Million) (2025-2032) By Country

Table 107: Europe Market Value (USD Million) (2025-2032) By Type

Table 108: Europe Market Value (USD Million) (2025-2032) By Application

Table 109: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 110: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 111: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 112: South America Market Value (USD Million) (2025-2032) By Country

Table 113: South America Market Value (USD Million) (2025-2032) By Type

Table 114: South America Market Value (USD Million) (2025-2032) By Application

Table 115: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 116: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 117: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 118: Global Morphine (MOP) Rapid Test Kit Market Volume (K) By Region

Table 119: Global Morphine (MOP) Rapid Test Kit Market Share (%) By Region (2025-2032)

Table 120: North America Market Volume (K) (2025-2032) By Country

Table 121: North America Market Volume (K) (2025-2032) By Type

Table 122: North America Market Volume (K) (2025-2032) By Application

Table 123: Europe Market Volume (K) (2025-2032) By Country

Table 124: Europe Market Volume (K) (2025-2032) By Type

Table 125: Europe Market Volume (K) (2025-2032) By Application

Table 126: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 127: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 128: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 129: South America Market Volume (K) (2025-2032) By Country

Table 130: South America Market Volume (K) (2025-2032) By Type

Table 131: South America Market Volume (K) (2025-2032) By Application

Table 132: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 133: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 134: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 135: Research Programs/Design For This Report

Table 136: Key Data Information From Secondary Sources

Table 137: Key Data Information From Primary Sources

FAQs

1. What is the current Morphine (MOP) Rapid Test Kit market size?

The Morphine (MOP) Rapid Test Kit market size reached roughly USD 1.15 billion in 2023, driven by expanding clinical diagnostics and law‑enforcement screening programs across North America and Europe, with emerging demand in Asia‑Pacific and Latin America markets.

2. What is the projected growth forecast for the market through 2030?

Forecasts indicate the Morphine (MOP) Rapid Test Kit market will expand at a compound annual growth rate of 6.2% from 2024 to 2030, reaching approximately USD 1.9 billion by the end of the forecast period globally.

3. Which factors are driving the market’s expansion?

Key drivers include heightened opioid abuse monitoring, increasing point‑of‑care testing adoption, stricter regulatory mandates for drug screening, and technological advances that lower assay time and cost, thereby encouraging broader implementation in hospitals, forensic labs, and correctional facilities.

4. What challenges could hinder market growth?

Major challenges involve high upfront equipment costs, limited reimbursement frameworks in certain regions, false‑positive concerns requiring confirmatory testing, and supply‑chain volatility for reagents, which may slow adoption among cost‑sensitive healthcare providers especially in developing markets.

5. Which regions are leading the market currently?

North America remains the dominant region, accounting for roughly 45% of sales, followed by Europe’s strong forensic sector. Rapid growth is observed in Asia‑Pacific, particularly China and India, where expanding clinical networks drive increased demand.

6. Who are the top companies competing in this space?

Leading players include Abbott Laboratories, Roche Diagnostics, Thermo Fisher Scientific, Siemens Healthineers, and Bio‑Rad Laboratories, each offering proprietary immunochromatographic platforms and leveraging extensive distribution networks to capture market share across clinical and law‑enforcement segments globally.

7. What future opportunities are emerging for the market?

The future outlook highlights opportunities in multiplexed panels that detect multiple opioids simultaneously, integration with digital health records, and expansion into home‑testing kits, which could open new revenue streams in telemedicine and addiction‑treatment monitoring globally.

8. How is technology influencing product development?

Advances such as nano‑particle labeling, smartphone‑based readers, and AI‑driven result interpretation are shortening assay times to under five minutes, improving sensitivity, and enabling decentralized testing, thereby reshaping the Morphine (MOP) Rapid Test Kit market landscape.

9. What is the regulatory environment like for these kits?

Regulatory oversight varies: the U.S. FDA class II devices requiring 510(k) clearance, while the EU follows the IVDR framework. Emerging markets are adopting harmonized standards, but divergent approval timelines can affect global rollout strategies significantly for manufacturers.

Contact for Full Report

Loading report content...

Morphine (MOP) Rapid Test Kit - Strategic Insights: Analysis 2025 and Forecasts 2033

Market Snapshot

Morphine (MOP) Rapid Test Kit Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Morphine (MOP) Rapid Test Kit Segmentation

Morphine (MOP) Rapid Test Kit Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Morphine (MOP) Rapid Test Kit market size?

2. What is the projected growth forecast for the market through 2030?

3. Which factors are driving the market’s expansion?

4. What challenges could hinder market growth?

5. Which regions are leading the market currently?

6. Who are the top companies competing in this space?

7. What future opportunities are emerging for the market?

8. How is technology influencing product development?

9. What is the regulatory environment like for these kits?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Morphine (MOP) Rapid Test Kit Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Morphine (MOP) Rapid Test Kit Segmentation

Morphine (MOP) Rapid Test Kit Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Morphine (MOP) Rapid Test Kit market size?

2. What is the projected growth forecast for the market through 2030?

3. Which factors are driving the market’s expansion?

4. What challenges could hinder market growth?

5. Which regions are leading the market currently?

6. Who are the top companies competing in this space?

7. What future opportunities are emerging for the market?

8. How is technology influencing product development?

9. What is the regulatory environment like for these kits?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation